Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, BI | - |
dc.contributor.author | Ahan, KB | - |
dc.contributor.author | Kang, MH | - |
dc.contributor.author | Kwon, OS | - |
dc.contributor.author | Hong, YS | - |
dc.contributor.author | Lee, JJ | - |
dc.contributor.author | Lee, HS | - |
dc.contributor.author | Ryu, JS | - |
dc.contributor.author | Kim, TY | - |
dc.contributor.author | Moon, DC | - |
dc.contributor.author | Song, S | - |
dc.contributor.author | Chung, YB | - |
dc.date.accessioned | 2024-01-21T05:12:05Z | - |
dc.date.available | 2024-01-21T05:12:05Z | - |
dc.date.created | 2021-09-03 | - |
dc.date.issued | 2005-04 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/136620 | - |
dc.description.abstract | We investigated the pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after intravenous (i.v.) bolus administration at a multiple dose every 24 h for 5 days in rats. To analyze ID-6105 levels in biological samples, we used an HPLC-based method which was validated in a pharmacokinetic study by suitable criteria. The concentrations of ID-6105 after the multiple administration for 5 days were not significantly different from the results after the single administration. The t(1/2 alpha), t(1/2 beta), V-dss and CLt after the multiple administration were not significantly different from the values after the single administration. Moreover, the concentrations of ID-6105 1 min at day 1-5 after i.v. bolus multiple administration did not show the significant difference. Of the various tissues, ID-6105 mainly distributed to the kidney, lung, spleen, adrenal gland, and liver after i.v. bolus multiple administration. ID-6105 concentrations in the kidney or lung 2 h after i.v. bolus administration were comparable to the plasma concentration shortly after i.v. bolus administration. However, the ID-6105 concentrations in various tissues 48 h after i.v. bolus administration decreased to low levels. ID-6105 was excreted largely in the bile after i.v. bolus multiple administration at the dose of 3 mg/kg. The amounts of ID-6105 found in the bile by 12 h or in the urine by 48 h after the administration were calculated to be 14.1% or 4.55% of the initial dose, respectively, indicating that ID-6105 is mostly excreted in the bile. In conclusion, ID-6105 was rapidly cleared from the blood and transferred to tissues, suggesting that ID-6105 might not be accumulated in the blood following i.v. bolus multiple dosages of 3 mg/kg every 24 h for 5 days. By 48 h after i.v. bolus administration, ID-6105 concentrations in various tissues had decreased to very low levels. The majority of ID-6105 appears to be excreted in the bile. | - |
dc.language | English | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after iv bolus multiple administration in rats | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/BF02977679 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.28, no.4, pp.476 - 482 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 28 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 476 | - |
dc.citation.endPage | 482 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.identifier.kciid | ART001086635 | - |
dc.identifier.wosid | 000228809700016 | - |
dc.identifier.scopusid | 2-s2.0-22844433404 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | STREPTOMYCES-GALILAEUS ATCC-31133 | - |
dc.subject.keywordPlus | AKLAVINONE 11-HYDROXYLASE GENE | - |
dc.subject.keywordPlus | BLOCKED MUTANT | - |
dc.subject.keywordPlus | ACLACINOMYCIN | - |
dc.subject.keywordPlus | ANTIBIOTICS | - |
dc.subject.keywordPlus | METABOLITES | - |
dc.subject.keywordPlus | CAESIUS | - |
dc.subject.keywordAuthor | 11-hydroxyaclacinomycin X (ID-6105) | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | multiple administration | - |
dc.subject.keywordAuthor | tissue distribution | - |
dc.subject.keywordAuthor | excretion | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.